The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
|Videos|January 24, 2018
Dr. Goetz Discusses a Secondary Analysis of the MONARCH Trials in Breast Cancer
Author(s)Matthew Goetz, MD
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Advertisement
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Advertisement
Related to this article
More than 76% of US counties have no TNBC trial, and only 9.8% of rural counties have one vs 47% of metropolitan counties, a new analysis finds.
At Rutgers Cancer Institute, neuro-oncologists met to discuss the latest trends in precision brain cancer care with FET-PET imaging, advanced molecular testing, and same-day multidisciplinary clinics.
Rural breast cancer deaths rise faster than urban rates, driven by low income, later diagnosis, and treatment gaps—warning of widening disparities by 2035.
Four oncologists share their perspectives on what is still limiting access to CAR T-cell therapies in 2026.
Breakthrough targeted therapies—from KRAS and PROTACs to CAR T—plus ctDNA monitoring and personalized vaccines push earlier detection and smarter cancer treatment.
J. Thaddeus Beck, MD, discusses how the shift from intravenous to subcutaneous formulations is changing oncology practice, from clinic logistics to patient preferences.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ESMO 2026 Presidential Symposium II Showcases OS-Improving LBAs in Lung and GI Cancers
2
FDA Approves Talazoparib/Enzalutamide in HRR-Mutated Prostate Cancer
3
ESMO 2026: Survival Gains and New Treatment Strategies in GI Cancers
4
ADCs Shine, Mixed Bag for Immunotherapy at ESMO 2026 Presidential Symposium III
5